JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus

Figure 2

CD49d median fluorescence intensity (MFI) measured on CD4+ and CD8+ T-lymphocyte subsets. CD49d expression assessed on the overall CD4+ (a) and CD8+ (b) T-lymphocytes and their subpopulations in peripheral blood of RRMS patients under natalizumab treatment are represented after stratification according to natalizumab infusion number. Statistical analysis was performed using a one-way ANOVA test for nonparametrical data (Kruskal–Wallis): for CD4, = 0.0004; CD4 N, > 0,05; CD4 CM, < 0,0001; CD4 EM, = 0.0022; CD4 E, < 0.0001; for CD8, = 0.01; CD8 I, < 0.0001; CD8 N, > 0.05; CD8 CM, < 0.0001; CD8 EM, < 0.0001; CD8 E, < 0.0001. Dunnett’s posttest was performed comparing each group with 0, and asterisks represent the level of statistical significance. Dashed line represents median value of CD49d expression observed in healthy donors. CD49d expression on CD4+ and CD8+ T-lymphocytes decreased from 0 to group with a linear trend (posttest for linear trend: < 0,0001 and = 0,0035, resp.). Lines and whiskers represent median values and interquartile ranges, respectively. N: naïve, CM: central memory, EM: effector memory, E: effectors, I: intermediate. 0: 0 infusions, 12: from 1 to 12 infusions, 24: from 13 to 24 infusions, 36: from 25 to 36 infusions, and : over 36 infusions of natalizumab. ; ; ; .

(a)

(b)